Liraglutide, also a GLP-1 receptor agonist, prevented the accumulation of Aβ plaques, decreased tau hyperphosphorylation and neurofilament proteins, prevented the loss of brain IR and synapses, and reversed cognitive and memory impairment in several mouse models of AD-like pathology and in a non-human primate model of AD [275,276,277]. The gene discussed is MAPT; the disease is memory impairment.